Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-<i>N</i>-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications
作者:Michael C. Van Zandt、Michael L. Jones、David E. Gunn、Leo S. Geraci、J. Howard Jones、Diane R. Sawicki、Janet Sredy、Jorge L. Jacot、A. Thomas DiCioccio、Tatiana Petrova、Andre Mitschler、Alberto D. Podjarny
DOI:10.1021/jm0492094
日期:2005.5.1
Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400
最近鉴定慢性糖尿病并发症的治疗方法的努力导致发现了一系列新型的高效和选择性的3-[((苯并噻唑-2-基)甲基]吲哚-N-链烷酸醛糖还原酶抑制剂。主要候选化合物3-[((4,5,7-三氟苯并噻唑-2-基)甲基]吲哚-N-乙酸(利多司他,9)抑制醛糖还原酶,IC(50)为5 nM,是5400倍对醛还原酶的活性较低,醛还原酶是一种与活性醛解毒有关的酶。在为期5天的STZ诱导的糖尿病大鼠模型中,它可降低神经和晶状体山梨糖醇的水平,ED(50)分别为1.9和4.5 mg / kg / d po。在3个月的糖尿病干预模型中(糖尿病1个月,随后2个月以5 mg / kg / d po进行药物治疗),相对于糖尿病对照,它可以使多元醇正常化,并减少运动神经传导速度不足59%。它具有良好的药代动力学特征(F,82%; t(1/2),5.6 h; Vd,0.694 L / kg),并且在目标组织中的良好药物渗透